Aripiprazole Tablet
Product Images NDC 33342-124

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 33342-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Aripiprazole Str)

Chemical structure of Aripiprazole, depicted as a molecular formula showing its atomic connections, including rings and functional groups relevant to its composition.*

FDA Label Image

Fig1 (Aripiprazole Fig 1)

A chart titled "Effect of Other Drugs on Aripiprazole" showing the fold change and 90% confidence interval of Aripiprazole's pharmacokinetic parameters (AUC and Cmax) when coadministered with various drugs. The x-axis represents the change relative to reference (without interacting drug). Different inhibitors, inducers, and other drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam are listed on the y-axis.*

FDA Label Image

Fig2 (Aripiprazole Fig 2)

A pharmacokinetic chart illustrating the effect of other drugs on the metabolism of Aripiprazole's active metabolite, Dehydro-Aripiprazole. The graph shows fold changes in pharmacokinetic parameters AUC and Cmax relative to a reference without interacting drugs, for various inhibitors, inducers, and other drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Fig3 (Aripiprazole Fig 3)

A pharmacokinetic forest plot showing fold change and 90% confidence intervals of various drugs/metabolites relative to a reference without interacting drug. The X-axis represents change relative to reference from 0.5 to 3.0, measuring parameters such as DM/DRP, AUC, and Cmax for substances including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and O-desmethylvenlafaxine.*

FDA Label Image

Fig4 (Aripiprazole Fig 4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' depicting the changes in AUC and Cmax relative to reference for special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The chart uses error bars to display fold changes and confidence intervals across these categories.*

FDA Label Image

Fig5 (Aripiprazole Fig 5)

A forest plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' illustrating the changes in AUC and Cmax values relative to reference for various factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severities, and severe renal impairment. The X-axis represents the fold change relative to reference, while the Y-axis lists the factors compared. Data points are presented with confidence intervals.*

FDA Label Image

Fig6 (Aripiprazole Fig 6)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over days from randomization between Aripiprazole (blue solid line) and placebo (red dashed line). The x-axis represents days from randomization (0 to 182), and the y-axis represents the proportion with relapse (0.0 to 1.0). Below the x-axis is a table indicating the number of subjects at risk for each group over time.*

FDA Label Image

Figure 9 (Aripiprazole Fig 9)

A line graph showing the change in YGTSS Total Tic Score from baseline over 8 weeks of treatment. It compares three groups: Aripiprazole Low dose, Aripiprazole High dose, and Placebo. The vertical axis represents the least-squares mean change in YGTSS total tic score, while the horizontal axis shows weeks of treatment. The graph indicates decreasing scores over time for all groups, with greater reductions for Aripiprazole High and Low doses compared to Placebo.*

FDA Label Image

222 (Aripiprazole 2mg 10x10)

Aripiprazole Tablets USP 2 mg oral tablets in a unit-dose packaging containing 100 tablets (10 x 10 unit dose). Manufactured by Macleods Pharmaceuticals Limited for Macleods Pharma USA, Inc. The label includes dosing instructions, storage temperature guidelines, and a barcode.*

FDA Label Image

333 (Aripiprazole 5mg 10x10)

Aripiprazole Tablets, USP 5 mg oral tablets packaging label by Macleods Pharmaceuticals Limited. The label shows a 100-count unit-dose carton with storage instructions at 20° to 25°C and a note that the package is not child-resistant. Manufactured by Macleods Pharmaceuticals Ltd, Baddi, Himachal Pradesh, India, for Macleods Pharma USA, Inc.*

FDA Label Image

444 (Aripiprazole 10mg 10x10)

Aripiprazole Tablets, USP 10 mg in oral tablet form by Macleods Pharmaceuticals Limited. The label includes the product name, strength (10 mg), manufacturer information, batch and expiration date placeholders, and storage instructions. Packaging indicates a 100-tablet count (10 x 10 unit dose). The label instructs pharmacists to provide the medication guide to patients and notes the package is not child-resistant.*

FDA Label Image

543 (Aripiprazole 15mg 10x10)

Label for Aripiprazole Tablets, USP 15 mg oral tablets by Macleods Pharmaceuticals Limited. The label shows the product name with strength prominently, manufacturer details, barcode, and packaging information for 100 tablets (10 x 10 unit dose). Storage instructions and a note on dispensing a medication guide are included.*

FDA Label Image

654 (Aripiprazole 20mg 10x10)

Packaging label for Aripiprazole Tablets, USP 20 mg oral tablets. The label shows Macleods Pharmaceuticals Limited as manufacturer, with Macleods Pharma USA, Inc. listed as the distributor. The package contains 100 tablets (10 x 10 unit dose) and includes storage instructions and a barcode. The label emphasizes the 20 mg strength and mentions that the package is not child-resistant.*

FDA Label Image

777 (Aripiprazole 30mg 10x10)

Packaging label for Aripiprazole Tablets, USP 30 mg oral tablets by Macleods Pharmaceuticals Limited. The label indicates the package contains 100 tablets in unit dose format. It includes storage instructions and notes that the unit-dose package is not child-resistant.*

FDA Label Image

123 (Aripiprazole 2mg 30s)

Aripiprazole Tablets USP 2 mg tablet label from Macleods Pharmaceuticals Limited. The label includes dosage strength 2 mg, a count of 30 tablets, storage instructions (20° to 25°C with permitted excursions), and manufacturing details from Macleods Pharma USA and Macleods Pharmaceuticals Ltd., India. Barcode and code HP/152/07 are also visible.*

FDA Label Image

333 (Aripiprazole 5mg 30s)

Label for Aripiprazole Tablets, USP 5 mg by Macleods Pharmaceuticals Limited. The oral tablet packaging indicates 30 tablets per container. The label includes storage instructions, barcode, and notes that the medication is prescription only. Manufacturer details list Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd.*

FDA Label Image

444 (Aripiprazole 10mg 30s)

Label for Aripiprazole Tablets, USP 10 mg oral tablets by Macleods Pharmaceuticals Limited. The label states each tablet contains 10 mg Aripiprazole and includes storage instructions (20° to 25°C with permitted excursions). It is for a bottle of 30 tablets, manufactured by Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. in India. The label includes NDC 33342-124-07 and a pharmacist dispensing note.*

FDA Label Image

666 (Aripiprazole 15mg 30s)

Aripiprazole Tablets USP 15 mg oral tablets label from Macleods Pharmaceuticals Limited. The label states each tablet contains 15 mg Aripiprazole, USP, and instructs the pharmacist to dispense the Medication Guide to each patient. It shows storage conditions and manufacturing details for Macleods Pharma USA and Macleods Pharmaceuticals Ltd India. The package contains 30 tablets.*

FDA Label Image

777 (Aripiprazole 20mg 30s)

Aripiprazole Tablets, USP 20 mg oral tablets label showing the product name, strength, dosage form, and package size of 30 tablets. The label includes the manufacturer's information: Macleods Pharma USA, Inc., and Macleods Pharmaceuticals Ltd. Storage instructions and a pharmacist dispensing note are also visible.*

FDA Label Image

565 (Aripiprazole 30mg 30s)

Label for Aripiprazole Tablets, USP 30 mg by Macleods Pharmaceuticals Limited. The oral tablet packaging indicates a 30-tablet count. It includes storage instructions, dosage advice to consult prescribing information, and notes the product is manufactured for Macleods Pharma USA and by Macleods Pharmaceuticals Ltd in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.